Line comprises eight grades of binderless borosilicate glass microfibre filter media for use as own-label or OEM products in medical and life sciences instruments
IW Tremont has recently completed a comprehensive product line development positioned for the OEM markets serving the medical and life sciences industries.
The core of the new line comprises eight grades of binderless borosilicate glass microfibre filter media, which the company says is ideally suited for applications in these fields.
This product grouping has been chosen to closely replicate many existing industry standard grades currently available from competing suppliers, which Tremont says have significantly higher price structures.
In addition to this product line, numerous other glass microfibre products such as reinforced, specialty treated, strengthened and process engineered materials are available.
Tremont says its glass microfibre materials are already part of some of the worlds leading life sciences and laboratory equipment products.
They are now available regardless of volume needs and current product development stage.
Perfectly suited for all stages of product development such as R and D, pilot production, full-scale production, phase out and maintenance.
During the development of this product line, careful consideration was given to finished product profit margin requirements.
Tremont says it has designed a competitive price structure typically demonstrating at least a 50% discount when compared to competitive products and producers.
The OEM programme further demonstrates its strengths when volume needs and budgets are small, it says.
"We pride ourselves on not asking the question 'How much do you need?' first", it says.
IW Tremont serves the analytical, diagnostic, life sciences and laboratory supply markets with filter and technical specialty media on a private label and OEM basis.
Specialising in glass microfibre filter media, it has numerous strategic marketing and converting relationships in place with leading production mills around the world.
It does not compete in the finished product segment of the medical and life sciences markets.
This means its products are always made readily available and cost effective to its customers, it says.
